New Two-Drug Immunotherapy Combo vs. Standard Immunotherapy for Advanced Lung Cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study compares a new combination of two immunotherapy drugs (sacituzumab tirumotecan plus pembrolizumab) versus pembrolizumab alone for people with advanced non-small cell lung cancer that has a high PD-L1 level (≥50%) and has not been treated yet. The goal is to see if the combination works better than the standard single immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced non-small cell lung cancer (NSCLC) with a PD-L1 level of 50% or higher on a recent biopsy.
- You have not had any prior cancer treatment for your advanced lung cancer (including chemotherapy, immunotherapy, or targeted drugs).
- You can carry out daily activities without significant help (ECOG performance status 0 or 1).
- You do not have active or untreated brain metastases, and you have no history of lung inflammation (pneumonitis) that needed steroids.
- You do not have an autoimmune disease that has needed treatment in the last two years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two newer drugs (sacituzumab tirumotecan and anlotinib) for people with extensive-stage small cell lung cancer that has progressed after one prior treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
This study tests a combination of two drugs for stage III lung cancer that can't be removed by surgery. One drug is an antibody-drug conjugate that targets cancer cells, and the other is an immunotherapy that helps your immune system fight cancer. The goal is to see if this combo shrinks or controls the tumor.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
This trial tests a new combination of two drugs for people with extensive-stage small cell lung cancer that has progressed after initial treatment. The goal is to see if this combination can help control the cancer.
This trial tests a combination of two drugs — a targeted chemotherapy and an immunotherapy — given before surgery for people with early-stage but locally advanced lung cancer. The goal is to see if this combination can shrink the tumor and improve outcomes.
This study tests a new combination of two drugs—sacituzumab tirumotecan (a targeted therapy) plus an immunotherapy—for people whose head and neck cancer has returned or spread after standard treatment. The goal is to see if this combination can shrink tumors and delay cancer growth.
Hear when a new Non-small Cell Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.